Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Insider Ingmar Bruns Purchases 20,000 Shares

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) insider Ingmar Bruns acquired 20,000 shares of the company’s stock in a transaction dated Thursday, February 6th. The stock was acquired at an average cost of $2.28 per share, with a total value of $45,600.00. Following the transaction, the insider now directly owns 36,629 shares of the company’s stock, valued at approximately $83,514.12. This represents a 120.27 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Zentalis Pharmaceuticals Stock Performance

Shares of ZNTL opened at $2.16 on Thursday. Zentalis Pharmaceuticals, Inc. has a one year low of $1.61 and a one year high of $18.07. The stock has a 50-day moving average price of $2.69 and a 200 day moving average price of $3.14. The company has a market capitalization of $153.92 million, a P/E ratio of -0.87 and a beta of 1.81.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last announced its earnings results on Tuesday, November 12th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.36. As a group, equities research analysts forecast that Zentalis Pharmaceuticals, Inc. will post -2.42 earnings per share for the current fiscal year.

Institutional Trading of Zentalis Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the stock. SG Americas Securities LLC boosted its stake in Zentalis Pharmaceuticals by 84.8% during the 3rd quarter. SG Americas Securities LLC now owns 26,149 shares of the company’s stock valued at $96,000 after acquiring an additional 11,997 shares during the last quarter. Exchange Traded Concepts LLC lifted its position in shares of Zentalis Pharmaceuticals by 195.3% during the third quarter. Exchange Traded Concepts LLC now owns 45,506 shares of the company’s stock worth $167,000 after purchasing an additional 30,098 shares during the last quarter. Wealth Enhancement Advisory Services LLC lifted its position in shares of Zentalis Pharmaceuticals by 44.3% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 67,893 shares of the company’s stock worth $250,000 after purchasing an additional 20,848 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its stake in Zentalis Pharmaceuticals by 63.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 13,676 shares of the company’s stock worth $50,000 after purchasing an additional 5,333 shares in the last quarter. Finally, Carson Advisory Inc. increased its holdings in Zentalis Pharmaceuticals by 55.8% in the third quarter. Carson Advisory Inc. now owns 24,570 shares of the company’s stock valued at $90,000 after buying an additional 8,800 shares during the last quarter.

Analyst Ratings Changes

ZNTL has been the subject of several recent research reports. Wells Fargo & Company lowered their price target on Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating for the company in a report on Thursday, January 30th. Guggenheim decreased their target price on Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating for the company in a research report on Friday, November 15th. UBS Group dropped their target price on Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. HC Wainwright decreased their price target on Zentalis Pharmaceuticals from $20.00 to $10.00 and set a “buy” rating for the company in a report on Wednesday, January 29th. Finally, Wedbush reaffirmed a “neutral” rating and issued a $4.00 price objective on shares of Zentalis Pharmaceuticals in a research report on Friday, January 24th. Five investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $8.24.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.